TY - JOUR AU - Parodis, Ioannis AU - Lindblom, Julius AU - Barturen, Guillermo AU - Ortega-Castro, Rafaela AU - Cervera, Ricard AU - Pers, Jacques-Olivier AU - Genre, Fernanda AU - Hiepe, Falk AU - Gerosa, Maria AU - Kovács, László AU - De Langhe, Ellen AU - Piantoni, Silvia AU - Stummvoll, Georg AU - Vasconcelos, Carlos AU - Vigone, Barbara AU - Witte, Torsten AU - Alarcón-Riquelme, Marta E AU - Beretta, Lorenzo ED - Pers, Jacques-Olivier / Collaborator ED - Saraux, Alain / Collaborator ED - Devauchelle-Pensec, Valérie / Collaborator ED - Jousse-Joulin, Sandrine / Collaborator ED - Lauwerys, Bernard / Collaborator ED - Ducreux, Julie / Collaborator ED - Maudoux, Anne-Lise / Collaborator ED - Tavares, Ana / Collaborator ED - Neves, Esmeralda / Collaborator ED - Faria, Raquel / Collaborator ED - Brandão, Mariana / Collaborator ED - Campar, Ana / Collaborator ED - Marinho, António / Collaborator ED - Farinha, Fátima / Collaborator ED - Almeida, Isabe / Collaborator ED - Gonzalez-Gay Mantecón, Miguel Angel / Collaborator ED - Alonso, Ricardo Blanco / Collaborator ED - Martínez, Alfonso Corrales / Collaborator ED - Rodríguez-Pintó, Ignasi / Collaborator ED - Espinosa, Gerard / Collaborator ED - Lories, Rik / Collaborator ED - Hunzelmann, Nicolas / Collaborator ED - Belz, Doreen / Collaborator ED - Baerlecken, Niklas / Collaborator ED - Zauner, Michael / Collaborator ED - Lehner, Michaela / Collaborator ED - Collantes, Eduardo / Collaborator ED - Angeles Aguirre-Zamorano, M A / Collaborator ED - Escudero-Contreras, Alejandro / Collaborator ED - Castro-Villegas, Ma Carmen / Collaborator ED - Ortego, Norberto / Collaborator ED - Fernández Roldán, María Concepción / Collaborator ED - Raya, Enrique / Collaborator ED - Moleón, Inmaculada Jiménez / Collaborator ED - Ramon, Enrique de / Collaborator ED - Quintero, Isabel Díaz / Collaborator ED - Meroni, Pier Luigi / Collaborator ED - Schioppo, Tommaso / Collaborator ED - Artusi, Carolina / Collaborator ED - Chizzolini, Carlo / Collaborator ED - Zuber, Aleksandra / Collaborator ED - Wynar, Donatienne / Collaborator ED - Balog, Attila / Collaborator ED - Deák, Magdolna / Collaborator ED - Bocskai, Márta / Collaborator ED - Dulic, Sonja / Collaborator ED - Kádár, Gabriella / Collaborator ED - Thiel, Silvia / Collaborator ED - Maresca, Manuel Rodriguez / Collaborator ED - López-Berrio, Antonio / Collaborator ED - Aguilar-Quesada, Rocío / Collaborator ED - Navarro-Linares, Héctor / Collaborator TI - Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort JF - ANNALS OF THE RHEUMATIC DISEASES J2 - ANN RHEUM DIS PY - 2024 SN - 0003-4967 DO - 10.1136/ard-2023-224795 UR - https://m2.mtmt.hu/api/publication/34656799 ID - 34656799 N1 - Export Date: 18 March 2024 CODEN: ARDIA Correspondence Address: Parodis, I.; Division of Rheumatology, Sweden; email: ioannis.parodis@ki.se Funding details: 2021-00436 Funding details: 2021-26, FoUI-955483 Funding details: Deutsche Forschungsgemeinschaft, DFG, 390874280, EXC 2155 Funding details: Karolinska Institutet, KI Funding details: Svenska Läkaresällskapet, SLS, OLL-974804, SLS-974449 Funding details: Stiftelsen Konung Gustaf V:s 80-årsfond, FAI-2020-0741 Funding details: Reumatikerförbundet, R-969696 Funding details: Innovative Medicines Initiative, IMI, 115565, 831434 Funding text 1: IP has received grants from the Swedish Rheumatism Association (R-969696), King Gustaf V’s 80-year Foundation (FAI-2020-0741), Swedish Society of Medicine (SLS-974449), Nyckelfonden (OLL-974804), Professor Nanna Svartz Foundation (2021-00436), Ulla and Roland Gustafsson Foundation (2021-26), Region Stockholm (FoUI-955483), and Karolinska Institute. This work was supported by EU/EFPIA/Innovative Medicines Initiative (IMI) Joint Undertaking (JU) PRECISESADS grant no. 115565 and IMI 2 JU (now HIH) 3TR grant no. 831434, and Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy, EXC 2155, project no. 390874280. AB - To unveil biological milieus underlying low disease activity (LDA) and remission versus active systemic lupus erythematosus (SLE).We determined differentially expressed pathways (DEPs) in SLE patients from the PRECISESADS project (NTC02890121) stratified into patients fulfilling and not fulfilling the criteria of (1) Lupus LDA State (LLDAS), (2) Definitions of Remission in SLE remission, and (3) LLDAS exclusive of remission.We analysed data from 321 patients; 40.8% were in LLDAS, and 17.4% in DORIS remission. After exclusion of patients in remission, 28.3% were in LLDAS. Overall, 604 pathways differed significantly in LLDAS versus non-LLDAS patients with an false-discovery rate-corrected p (q)<0.05 and a robust effect size (dr)≥0.36. Accordingly, 288 pathways differed significantly between DORIS remitters and non-remitters (q<0.05 and dr≥0.36). DEPs yielded distinct molecular clusters characterised by differential serological, musculoskeletal, and renal activity. Analysis of partially overlapping samples showed no DEPs between LLDAS and DORIS remission. Drug repurposing potentiality for treating SLE was unveiled, as were important pathways underlying active SLE whose modulation could aid attainment of LLDAS/remission, including toll-like receptor (TLR) cascades, Bruton tyrosine kinase (BTK) activity, the cytotoxic T lymphocyte antigen 4 (CTLA-4)-related inhibitory signalling, and the nucleotide-binding oligomerization domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome pathway.We demonstrated for the first time molecular signalling pathways distinguishing LLDAS/remission from active SLE. LLDAS/remission was associated with reversal of biological processes related to SLE pathogenesis and specific clinical manifestations. DEP clustering by remission better grouped patients compared with LLDAS, substantiating remission as the ultimate treatment goal in SLE; however, the lack of substantial pathway differentiation between the two states justifies LLDAS as an acceptable goal from a biological perspective. LA - English DB - MTMT ER - TY - JOUR AU - Fanouriakis, Antonis AU - Kostopoulou, Myrto AU - Andersen, Jeanette AU - Aringer, Martin AU - Arnaud, Laurent AU - Bae, Sang-Cheol AU - Boletis, John AU - Bruce, Ian N AU - Cervera, Ricard AU - Doria, Andrea AU - Dörner, Thomas AU - Furie, Richard A AU - Gladman, Dafna D AU - Houssiau, Frederic A AU - Inês, Luís Sousa AU - Jayne, David AU - Kouloumas, Marios AU - Kovács, László AU - Mok, Chi Chiu AU - Morand, Eric F AU - Moroni, Gabriella AU - Mosca, Marta AU - Mucke, Johanna AU - Mukhtyar, Chetan B AU - Nagy, György AU - Navarra, Sandra AU - Parodis, Ioannis AU - Pego-Reigosa, José M AU - Petri, Michelle AU - Pons-Estel, Bernardo A AU - Schneider, Matthias AU - Smolen, Josef S AU - Svenungsson, Elisabet AU - Tanaka, Yoshiya AU - Tektonidou, Maria G AU - Teng, Yk Onno AU - Tincani, Angela AU - Vital, Edward M AU - van Vollenhoven, Ronald F AU - Wincup, Chris AU - Bertsias, George AU - Boumpas, Dimitrios T TI - EULAR recommendations for the management of systemic lupus erythematosus. 2023 update TS - 2023 update JF - ANNALS OF THE RHEUMATIC DISEASES J2 - ANN RHEUM DIS VL - 83 PY - 2024 IS - 1 SP - 15 EP - 29 PG - 15 SN - 0003-4967 DO - 10.1136/ard-2023-224762 UR - https://m2.mtmt.hu/api/publication/34193576 ID - 34193576 N1 - Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece Lupus Europe, Copenhagen, Denmark Division of Rheumatology, Department of Medicine III, University Medical Center, Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Centre National de Référence des Maladies Auto-immunes Systémiques Rares (RESO), Strasbourg, France Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, South Korea Department of Nephrology and Renal Transplantation Unit, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin; Deutsches Rheumaforschungszentrum, Berlin, Germany Division of Rheumatology, Northwell Health, Great Neck, New York City, NY, United States Lupus Program, Centre for Prognosis Studies in the Rheumatic Disease, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada Service de Rhumatologie, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium Department of Rheumatology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal Department of Medicine, University of Cambridge, Cambridge, United Kingdom Cyprus League Against Rheumatism, Aglantzia, Cyprus Department of Rheumatology and Immunology, Faculty of Medicine, University of Szeged, Hungary Department of Medicine, Tuen Mun Hospital, Hong Kong Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, VIC, Australia Department of Biomedical Sciences Humanitas University, Nephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Milan, Italy Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy Department of Rheumatology & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany Vasculitis Service, Rheumatology Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary Heart and Vascular Center, Semmelweis University, Budapest, Hungary Section of Rheumatology, Department of Medicine, University of Santo Tomas, Manila, Philippines Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden Rheumatology Department, Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) - VIGO Group, Galicia Sur Health Research Institute, Vigo, Spain Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States Grupo Oroño, Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan Rheumatology Unit, First Department of Propaedeutic Internal Medicine, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Joint Academic Rheumatology Program, Athens, Greece Centre of Expertise for Lupus-, Vasculitis- and Complement-mediated Systemic autoimmune diseases, Department of Internal Medicine - section Nephrology, Leiden University Medical Center, Leiden, Netherlands Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands Department of Rheumatology, King's College Hospital, London, United Kingdom Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, University Hospital of Heraklion, Heraklion, Greece Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Medical School, University of Cyprus, Nicosia, Cyprus Cited By :49 Export Date: 24 April 2024 CODEN: ARDIA Correspondence Address: Boumpas, D.T.; Rheumatology and Clinical Immunology Unit, Greece; email: boumpasd@uoc.gr AB - To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence.An international Task Force formed the questions for the systematic literature reviews (January 2018-December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item.The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease.The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, László TI - Beszámoló a Magyar Reumatológusok Egyesülete és a Magyar Reumatológiai Szakdolgozók Egyesülete idei vándorgyűléséről (Szeged, 2023. szeptember 21-23) JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 4 SP - 223 EP - 225 PG - 3 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34477494 ID - 34477494 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Farkas, Viktória AU - Kovács, László TI - A szisztémás lupus erythematosus diagnosztikája JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 15 PY - 2023 IS - 3 SP - 61 EP - 71 PG - 11 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/34191432 ID - 34191432 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Rideg, Adrienn AU - Dobi, Diána AU - Kovács, László TI - Katasztrófa antifoszfolipid szindróma egy eset kapcsán JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 181 EP - 182 PG - 2 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149983 ID - 34149983 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Ladóczky-Hulló, Daniella AU - Bocskai, Márta AU - Kovács, László TI - Differenciáldiagnosztikai kihívás nyelőcső motilitási zavar kapcsán JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 172 EP - 173 PG - 2 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149961 ID - 34149961 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szabó, Enikő AU - Bodor, Gergely AU - Kovács, László AU - Szebeni, J. Gábor TI - Többparaméteres áramlási citometria az egészséges és SLE-s immunsejt populációk glikozilációs különbségeinek felderítésére JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 159 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149949 ID - 34149949 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Honfi, Dániel György AU - Kovács, László TI - ANCA-asszociált vasculitisek klinikai spektrumának vizsgálata JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 152 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149940 ID - 34149940 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Hemelein, Rita Adrienn AU - Kata, Diána AU - Hegedűs, Éva AU - Rideg, Adrienn AU - Datki, Zsolt AU - Földesi, Imre AU - Kovács, László AU - Pákáski, Magdolna AU - Kálmán, János TI - Kognitív funkció zavarokkal összefüggő biomarkerek vizsgálata rheumatoid arthritisben és systemas lupus erythematosusban JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 150 EP - 151 PG - 2 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149932 ID - 34149932 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Bodor, Gergely AU - Takács, Martin AU - Kovács, László TI - Cyclophospamid és rituximab összehasonlítása súlyos szisztémás lupus erythematosus kezelésében JF - MAGYAR REUMATOLÓGIA J2 - MAGYAR REUMATOL VL - 64 PY - 2023 IS - 3 SP - 146 SN - 0139-4495 UR - https://m2.mtmt.hu/api/publication/34149925 ID - 34149925 LA - Hungarian DB - MTMT ER -